Tocilizumab biosimilar - EPIRUS Biopharmaceuticals

Drug Profile

Tocilizumab biosimilar - EPIRUS Biopharmaceuticals

Alternative Names: BOW-070

Latest Information Update: 01 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Giant lymph node hyperplasia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 09 May 2016 Discontinued - Preclinical for Rheumatoid arthritis in USA (IV)
  • 09 May 2016 Preclinical trials in Giant lymph node hyperplasia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top